Signaling molecule improved ovarian cell function in the lab
Lab experiments using human and aged-mouse ovarian cells found greater energy production and hormone secretion after exposure to prostaglandin D2.
Our read
Interventions- Studied:
- Experiments in human and aged-mouse ovarian cells and embryos
- What changed:
- Ovarian cells produced more energy after exposure to prostaglandin D2
- The catch:
- Experiments covered cells and early embryos, not fertility outcomes in living animals
- In the record:
- One of 3 papers on Prostaglandin D2 on record: none yet with results in people.
- Why it’s aging research:
- It studies organisms or tissues that aged naturally.
Editor of record: Boris Djordjevic · AgingResearch.News
The laboratory experiments used human granulosa (KGN) cells, primary ovarian cells from aged mice, and embryos before implantation. Granulosa cells support developing eggs. Researchers tested prostaglandin D2, a signaling lipid molecule.
In the ovarian cell experiments, the molecule restored networks formed by mitochondria, the cells’ energy-producing components. It increased energy production and secretion of the hormones estradiol and progesterone. The researchers also reported lower activity of an enzyme associated with senescence, a state in which cells stop dividing. In embryos, prostaglandin D2 increased the voltage across mitochondrial membranes, a measure of mitochondrial function. It also accelerated early cell divisions and improved progression to the morula and blastocyst stages, successive stages of development before implantation.
Why it matters
The work explored whether changing cellular energy systems could help address aging-associated ovarian dysfunction. The authors proposed prostaglandin D2 as a potential way to improve reproductive outcomes in that setting.
Caveats
The evidence came from laboratory experiments in cells and early embryos. Improvements in these systems do not establish fertility benefits in living animals or people.
The paper
CHA University
Biomedicine & Pharmacotherapy, May 23, 2026, Open access
Comments
Be the first to comment.